BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Posts falsely claim Netanyahu video fabricated to cover up his death - 2Step by step instructions to Pick A Keep money with High Fixed Store Loan costs
- 3From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- 4Exploring the Main Year of Life as a parent: Individual Encounters
- 5Fundamental Archives for Beginning Your Business
- The Most Paramount Crossroads in Olympic History
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- Favored Organic product for Seniors' Prosperity: Make Your Determination
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- 6 Savvy Locks for Lofts
- Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz
- Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
